Sage Therapeutics Stock News

Sage Therapeutics Inc. (NASDAQ:SAGE) price on Friday, February 11, fall -0.81% below its previous days close as a downside momentum from buyers pushed the stocks value to $43.04. A look at the stocks price movement, the close in the last trading session was $43.39, moving within a range at $42.56 and $44.50. The beta value Thinking Of Buying Sage Therapeutics Inc. (NASDAQ: SAGE) Stock? Heres What You Need To Know Read More »

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast on Thursday, February 24, 2022 at 8:00 a.m. ET to announce fourth quarter and full year 2021 financial results and discuss recent business updates. The webcast can be accessed on the investor page of Sage''s website at

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double.

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double

In last trading session, Sage Therapeutics Inc. (NASDAQ:SAGE) saw 0.7 million shares changing hands with its beta currently measuring 1.73. Company’s recent per share price level of $42.02 trading at $1.43 or 3.52% at ring of the bell on the day assigns it a market valuation of $2.36B. That closing price of SAGE’s stock is … Sage Therapeutics Inc. (NASDAQ:SAGE) Adds 8.24% In A Week: What’s Taking The Stock Higher? Read More »

A new thematic ETF providing exposure to the medicinal psychedelic drug industry, PSYK ETF, has just been launched.

Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions. The PSYK ETF (NYSE: PSYK)

A new thematic ETF providing exposure to the medicinal psychedelic drug industry, PSYK ETF, has just been launched.

Taro (TARO) delivered earnings and revenue surprises of -23.08% and 2.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Following recent updates from numerous management teams within the health care space, Needham analyst Ami Fadia has reevaluated the stocks in the firm's coverage universe using a stock selection crit

The latest snub for Aduhelm does not bode well for this company's future.